Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · July 12, 2023

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab–Ipilimumab Therapy in Patients With Advanced Melanoma

JAMA Network Open


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Network Open
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
JAMA Netw Open 2023 Jun 01;6(6)e2319607, M Gupta, I Stukalin, D Meyers, S Goutam, DYC Heng, T Cheng, J Monzon, V Navani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading